A roundup published on November 19, 2026, brought together analyst rating changes, new coverage and reiterated calls across technology, insurance and other sectors. The ratings and price targets below are the firms’ views, not forecasts of confirmed outcomes.
Technology and communications
- Anthropic: Wolfe initiated coverage with an outperform rating, calling the company “best-in-class” and projecting substantial revenue growth by 2028.
- Apple: JPMorgan reiterated its overweight rating. It said its consumer survey found iPhone purchase intent at a five-year high, led by existing users looking to upgrade, while interest from people switching brands moderated for a second consecutive year.
- Box: UBS upgraded the company to buy from neutral, citing signs that AI-related workflows could accelerate growth.
- NXP Semiconductors: StoneX initiated coverage with a buy rating, describing the company as a growth story.
- SpaceX: Morgan Stanley reiterated an overweight call and described it as a potential pick for a portfolio focused on resilience. The roundup did not explain the quoted “SPCX” reference.
- Synopsys: Barclays initiated coverage at overweight, citing its position in electronic design automation and potential demand for AI-related tools.
- Nvidia: Daiwa reiterated outperform but cut its price target to $185 from $245. It said results remained strong while raising questions about the durability of AI spending and eventual CEO succession.
- MongoDB: UBS assumed coverage with a buy rating, citing what it sees as durable growth.
Insurance, health care and finance
- Viridian Therapeutics: Bank of America initiated coverage at buy with a $47 price objective. It described the company as focused on thyroid eye disease and other autoimmune conditions.
- Kingstone Companies: Piper Sandler initiated coverage at overweight with a $24 price target, citing a potential turnaround.
- Unum Group: UBS upgraded the insurer to buy from neutral. Its quoted assessment pointed to potential upside of about 8% to 2027 consensus earnings per share from improving mortality and said risk transfer had reduced long-term-care exposure.
- Reinsurance Group of America: UBS upgraded the company to buy from neutral and raised its price target to $325 from $236, citing what it called durable earnings strength.
- Brown & Brown and Marsh & McLennan: Wells Fargo upgraded both to overweight from equal weight. It pointed to a lower hurdle for Brown & Brown’s organic growth and potential 2027 earnings upside for Marsh & McLennan from acquisitions.
- Abbott Laboratories: Leerink upgraded the company to outperform from market perform, saying its assessment of the risk-reward balance had improved.
- Outlook Therapeutics: Piper Sandler initiated coverage at overweight with a $4 price target.
- Strategy: Monness Crespi Hardt downgraded the company to sell from neutral, citing bitcoin-related risk, leverage and the stock’s premium to its bitcoin holdings. The firm estimated that each $1,000 change in bitcoin’s price would translate to a $2.00 change in Strategy’s share price.
Consumer, industrial and other calls
- Harley-Davidson: StoneX initiated coverage at buy with a $40 price target. Its case included the company’s net cash position and an expected return of entry-level motorcycles in fiscal 2027.
- Vylor: Barclays initiated coverage at overweight with an $83 price target, describing it as a leading seed company.
- BBB Foods: Barclays initiated coverage at overweight with a $90 price target, citing growth potential.
- Super Group: Rothschild & Co Redburn initiated coverage at buy, pointing to its position in South Africa’s online gambling market and potential growth elsewhere in Africa.
- Expeditors International: Citizens upgraded the shares to market outperform from market perform and set a $240 price target, citing higher earnings-per-share expectations.
- Unusual Machines: Oppenheimer initiated coverage at outperform with a $30 target over 12 to 18 months.
- HawkEye 360: Oppenheimer initiated coverage at outperform with a $30 target over 12 to 18 months, arguing that demand for radio-frequency detection exceeds what government systems can supply.
- Bloom Energy: BMO upgraded the company to outperform from market perform but lowered its price target to $230 from $260, citing lower valuation multiples across power infrastructure.
- AST SpaceMobile: B. Riley upgraded the company to buy from hold. It said the risk-reward balance had improved with shares at $25.49 and cited potential benefits from successful rocket development.
- Swarmer: Oppenheimer initiated coverage at outperform with a $20 target over 12 to 18 months.
